A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B
Phase of Trial: Phase I/II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs ABI-H0731 (Primary) ; Entecavir; Peginterferon alfa-2a; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 02 Jan 2018 Planned number of patients changed from 80 to 84.
- 02 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.